Notoginseng (san qi) Panax notoginseng (Burkill) F.H.Chen
Also called: san qi, sanqi, Sanchi, Panax notoginseng
Notoginseng (Panax notoginseng) is a ginseng relative native from southeastern Yunnan, China, to northern Vietnam, and a widely used Chinese medicinal herb. Its root is used; human trials have tested oral root preparations and notoginseng saponin products, some given by injection.
- Category
- Botanical
- Part used
- Root; trials used oral root preparations or Panax notoginseng saponin (PNS) extracts, given orally or (in most stroke trials) by intravenous injection
- Strongest evidence
- B Some positive trials
- Native range
- Native range (POWO): China (SE. Yunnan) to N. Vietnam; POWO lists it as extinct in China South-Central
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2013 systematic review included 17 RCTs (1,747 participants) of oral Panax notoginseng preparations, mostly Xuesaitong soft capsules of notoginseng saponins, in coronary heart disease; trials adding other herbs and injection trials were excluded. [1]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Angina in coronary heart disease (oral preparations added to usual care) | B | A 2013 systematic review of 17 RCTs (1,747 participants) found oral P. notoginseng eased angina symptoms but did not significantly reduce cardiovascular events; small samples and potential bias limited confidence. [1] |
| Unstable angina (oral Panax notoginseng saponins) | B | A 2018 meta-analysis of 17 RCTs reported fewer and shorter angina attacks and lower nitroglycerin use; authors called for multi-center, large, high-quality trials. [2] |
| Acute ischemic stroke (Xuesaitong, a Panax notoginseng saponin product, mostly given by intravenous injection) | B | A 2023 meta-analysis of 46 RCTs (7,957 patients; 43 used intravenous injection, 3 oral forms) reported better functional outcomes; certainty was moderate to very low, risk of bias was high, and mortality did not differ. [3] |
Main constituents: Saponins, including ginsenoside Rb1, ginsenoside Rg1 and notoginsenoside R1, named as its main active ingredients [4]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines1 listed
Aspirin
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications3 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Four elderly patients developed a pustular drug eruption with fever within a week of starting Panax notoginseng saponin injection; all needed high-dose, long-term glucocorticoid therapy. [5]
- In the 2018 meta-analysis of oral notoginseng saponins, 9 of 17 RCTs described adverse events; the authors concluded oral PNS 'is safe up to now' but asked for higher-quality trials. [2]
- In the 2023 stroke meta-analysis of Xuesaitong (43 of 46 trials used intravenous injection), the incidence of adverse events did not differ significantly from control groups. [3]
Interactions
| With | What happens |
|---|---|
| Aspirin | A 2022 meta-analysis of 20 RCTs (2,216 patients) found P. notoginseng preparations (oral capsules or tablets, or Xuesaitong injection) plus aspirin inhibited platelet aggregation more than aspirin alone, without a significant difference in bleeding-related events. [6] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Root samples from major producing areas in Yunnan averaged 0.43 mg/kg cadmium, above China's 0.3 mg/kg standard for herbal medicine. [7]
- A 2026 study used microscopy plus HPLC-UV to authenticate Panax species, including P. notoginseng; the adulterants Codonopsis pilosula and Platycodon grandiflorus lacked the eight major ginsenosides. [8]
Regulatory status
- US: FDA's published NDI notification list has 3 entries naming Panax notoginseng (earliest NDI 212 submitted 2003-03-07; most recent NDI 610 submitted 2009-09-09, a combined Astragalus membranaceus and P. notoginseng root extract). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [9]
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [10]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 3 entries naming Panax notoginseng (earliest NDI 212 submitted 2003-03-07; most recent NDI 610 submitted 2009-09-09). NDI 610 is a combined extract of Astragalus membranaceus and P. notoginseng roots. Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Aspirin: A 2022 meta-analysis of 20 RCTs (2,216 patients) found P. notoginseng preparations (oral capsules or tablets, or Xuesaitong injection) plus aspirin inhibited platelet aggregation more than aspirin alone, without a significant difference in bleeding-related events. [P6]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- A 2026 study of four Panax species, including P. notoginseng, names Codonopsis pilosula and Platycodon grandiflorus as common adulterants; both lacked the eight major ginsenosides found in Panax samples. [P7]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component — US cGMP rule for dietary supplements: at least one appropriate test or examination must verify the identity of any component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)); exemption only through a petition FDA grants (111.75(a)(1)(ii)). [P8]
- Cadmium — Root samples from major producing areas in Yunnan averaged 0.43 mg/kg cadmium, above China's 0.3 mg/kg standard for herbal medicine (2016 study). [P9]
- Microscopy of root or powder plus HPLC-UV ginsenoside profile — Secretory ducts, starch grains and xylem features separate Panax roots from adulterants, and HPLC-UV showed adulterants lack the eight major ginsenosides. [P7]
Supply and conservation
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Yang F, Ma Q, Matsabisa MG, Chabalala H, Braga FC, Tang M. Panax notoginseng for cerebral ischemia: a systematic review. Am J Chin Med 2020;48(6):1331-1351 (PMID 32907361), 2020-09-09. pubmed.ncbi.nlm.nih.gov
- Duan L, Xiong X, Hu J, Liu Y, Wang J. Efficacy and safety of oral Panax notoginseng saponins for unstable angina patients: a meta-analysis and systematic review. Phytomedicine 2018;47:23-33 (PMID 30166105), 2018-08-01. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (list data last updated 2026-07-23; retrieved October 29, 2026), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (list retrieved October 29, 2026), 2026-10-29. ntp.niehs.nih.gov
- Dai L, Zhang Y, Jiang Y, Chen K. Panax notoginseng preparation plus aspirin versus aspirin alone on platelet aggregation and coagulation in patients with coronary heart disease or ischemic stroke: a meta-analysis of randomized controlled trials. Front Pharmacol 2022;13:1015048 (PMID 36569332), 2022-12-07. pubmed.ncbi.nlm.nih.gov
- Külkamp J, Osman AG, Katragunta K, Avula B, Khan IA, Chittiboyina AG. Microscopy combined with LC-UV analysis as a tool for authentication of ginseng species used in traditional medicine and detection of their adulterants. J Diet Suppl 2026;23(4):475-489 (PMID 42262747), 2026-06-09. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of October 23, 2026), 2026-10-23. ecfr.gov
- Zhu M, Jiang Y, Cui B, et al. Cadmium accumulation in Panax notoginseng: levels, affecting factors and the non-carcinogenic health risk. Environ Geochem Health 2016;38:423-35 (PMID 26070861), 2016-04. pubmed.ncbi.nlm.nih.gov
- GBIF species API: IUCN Red List category for Panax notoginseng (Burkill) F.H.Chen ex C.H.Chow (usageKey 8877811), 2026-10-29. api.gbif.org
Sources
- Shang Q, Xu H, Liu Z, Chen K, Liu J. Oral Panax notoginseng preparation for coronary heart disease: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med 2013;2013:940125 (PMID 24023585), 2013-08-20. pubmed.ncbi.nlm.nih.gov
- Duan L, Xiong X, Hu J, Liu Y, Wang J. Efficacy and safety of oral Panax notoginseng saponins for unstable angina patients: a meta-analysis and systematic review. Phytomedicine 2018;47:23-33 (PMID 30166105), 2018-08-01. pubmed.ncbi.nlm.nih.gov
- Shi X, Feng L, Li Y, et al. Efficacy and safety of Panax notoginseng saponins (Xuesaitong) for patients with acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2023;14:1280559 (PMID 37908976), 2023-10-16. pubmed.ncbi.nlm.nih.gov
- Yang F, Ma Q, Matsabisa MG, Chabalala H, Braga FC, Tang M. Panax notoginseng for cerebral ischemia: a systematic review. Am J Chin Med 2020;48(6):1331-1351 (PMID 32907361), 2020-09-09. pubmed.ncbi.nlm.nih.gov
- Yin Z, Ma L, Xu J, Xia J, Luo D. Pustular drug eruption due to Panax notoginseng saponins. Drug Des Devel Ther 2014;8:957-61 (PMID 25114505), 2014-07-16. pubmed.ncbi.nlm.nih.gov
- Dai L, Zhang Y, Jiang Y, Chen K. Panax notoginseng preparation plus aspirin versus aspirin alone on platelet aggregation and coagulation in patients with coronary heart disease or ischemic stroke: a meta-analysis of randomized controlled trials. Front Pharmacol 2022;13:1015048 (PMID 36569332), 2022-12-07. pubmed.ncbi.nlm.nih.gov
- Zhu M, Jiang Y, Cui B, et al. Cadmium accumulation in Panax notoginseng: levels, affecting factors and the non-carcinogenic health risk. Environ Geochem Health 2016;38:423-35 (PMID 26070861), 2016-04. pubmed.ncbi.nlm.nih.gov
- Külkamp J, Osman AG, Katragunta K, Avula B, Khan IA, Chittiboyina AG. Microscopy combined with LC-UV analysis as a tool for authentication of ginseng species used in traditional medicine and detection of their adulterants. J Diet Suppl 2026;23(4):475-489 (PMID 42262747), 2026-06-09. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (Royal Botanic Gardens, Kew). Panax notoginseng (Burkill) F.H.Chen (retrieved October 29, 2026), 2026-10-29. powo.science.kew.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.